Dulaglutide

CHEMBL2108027 Phase 4 승인됨 Protein
Half-Life
5 days
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A long-acting GLP-1 receptor agonist injected weekly to improve blood sugar control in adults with type 2 diabetes. It also provides cardiovascular benefits and may promote weight loss.

치료 영역

약물 분류

작용 기전

GLP-1 receptor agonist fused to Fc fragment; enhances glucose-dependent insulin secretion.

Pharmacokinetics (PK)

Half-Life 5 days

Pharmacodynamics (PD)

기전

GLP-1 receptor agonist fused to Fc fragment; enhances glucose-dependent insulin secretion.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A long-acting GLP-1 receptor agonist injected weekly to improve blood sugar control in adults with type 2 diabetes. It also provides cardiovascular benefits and may promote weight loss.

GLP-1 receptor agonist fused to Fc fragment; enhances glucose-dependent insulin secretion.

Key pharmacokinetic parameters for Dulaglutide: Half-life: 5 days.

Yes, Dulaglutide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108027. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.